X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Acta Pharmaceutica Sinica B

期刊標題檢索 ACTA PHARM SIN 最新評論: You can submit something else, no problem. Anything sent directly to t... (2024-11-07)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Acta Pharmaceutica Sinica B]您好,您是該頁面的第 202577 位訪客。

期刊簡介
期刊名稱Acta Pharmaceutica Sinica B Acta Pharmaceutica Sinica B
LetPub Score
8.3
51 ratings
Rate

Reputation
8.9

Influence
7.6

Speed
8.7

期刊簡稱ACTA PHARM SIN B
ISSN2211-3835
E-ISSN2211-3843
h-index28
CiteScore
CiteScoreSJRSNIPCiteScore Rank
22.403.0352.253
Subject fieldQuartilesRankPercentile
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: General Pharmacology, Toxicology and Pharmaceutics
Q11 / 80

自引率 (2023-2024)5.40%自引率趨勢
掲載範囲
Acta Pharmaceutica Sinica B (APSB) is a bimonthly journal, in English, which publishes significant original research articles, rapid communications and high quality reviews of recent advances in all areas of pharmaceutical sciences — including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics.
官方網站https://www.journals.elsevier.com/acta-pharmaceutica-sinica-b
在線稿件提交https://www.editorialmanager.com/APSB
開放訪問Yes
出版商Elsevier BV
主題領域Pharmacology, Toxicology and Pharmaceutics
出版國/地區Netherlands
發行頻率
創刊年0
每年文章數300每年文章數趨勢
黃金OA百分比98.22%
OA Related Info
APC: No
APC waiver:Check Notes
Other charges: No
Keywords: pharmaceutical science、traditional chinese medicine、pharmaceutics、pharmaceutical chemistry、pharmacokinetics
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
PHARMACOLOGY & PHARMACYSCIEQ15/354
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2211-3835%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 19 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Acta Pharmaceutica Sinica B】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    Antibiotics-BaselH-index: 0

    CiteScore: 7.30
    Pharmacology Research & PerspectivesH-index: 0

    CiteScore: 5.30
    Therapeutics and Clinical Risk ManagementH-index: 0

    CiteScore: 5.30
    Revista Brasileira de Farmacognosia-Brazilian Journal of PharmacognosyH-index: 37

    CiteScore: 2.60
    Infarma Pharmaceutical SciencesH-index: 0

    CiteScore: 0.10
    Mental Health ClinicianH-index: 0

    CiteScore: 1.90
    Pharmacological Research Modern Chinese MedicineH-index: 0

    CiteScore: 1.60
    學科內最受檢索的期刊 頁面查看次數
    Antibiotics-Basel33464
    Pharmacology Research & Perspectives17138
    Revista Brasileira de Farmacognosia-Brazilian Journal of Pharmacognosy15828
    Therapeutics and Clinical Risk Management5962
    Infarma Pharmaceutical Sciences1581
    Pharmacological Research Modern Chinese Medicine1297
    Mental Health Clinician418
  •  

    Acta Pharmaceutica Sinica B Acta Pharmaceutica Sinica B
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/9)
  [Acta Pharmaceutica Sinica B] 的評論撰寫評論
作者: asd3204


領域: 医学
審稿時間: 5.0 month(s)
結果: 修改後接受


撰寫評論

2024-11-07 22:47:41 評論於
You can submit something else, no problem. Anything sent directly to the editor after the deadline will be rejected, without exception.
(0) 讚! | asd3204

作者: Tan-Xin


領域: 材料科学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-11-03 16:24:21 評論於
After submission, it was with the editor. Then it was DIP. Does this mean it has been rejected, and can I prepare to submit to other journals?
(0) 讚! | Tan-Xin

作者: 一条小春豪


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-10-19 21:00:44 評論於
Friend, has your status changed? I am also DIP now.
(0) 讚! | 一条小春豪

作者: 龙鳞新峰


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-10-15 16:56:02 評論於
Please translate the following passage into English: None
(0) 讚! | 龙鳞新峰

作者: 辉666


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-10-12 10:18:37 評論於
How long does the with editor stage last?
(0) 讚! | 辉666

作者: 暗月寺乐安


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-10-11 20:37:11 評論於
Do they need a full wrap for their WB?
(0) 讚! | 暗月寺乐安

作者: accept !!!


領域: 生物学
審稿時間: 4.0 month(s)
結果: 拒稿


撰寫評論

2024-10-10 18:14:51 評論於
It took them 3 months and 10 days to reject me, it hurts, it's too slow, okay?
(0) 讚! | accept !!!

作者: 桂枝小郎君


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-10-09 19:29:50 評論於
May I ask what is going on behind?
(0) 讚! | 桂枝小郎君

作者: 桂枝小郎君


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-10-09 19:24:49 評論於
How did it go later on?
(0) 讚! | 桂枝小郎君

作者: 桂枝小郎君


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-10-09 19:24:31 評論於
May I ask what happened afterwards?
(0) 讚! | 桂枝小郎君

作者: 桂枝小郎君


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-10-09 15:33:12 評論於
Review speed: 24.0 | Submission hit rate: 5.0 Experience sharing: so slow
(0) 讚! | 桂枝小郎君

作者: 念香Sama


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-09-25 19:31:57 評論於
I submitted on 9.25 and the next day on 9.26, it was already in the decision in process status. Does this mean that I will be rejected and there is no possibility of being under review again?
(0) 讚! | 念香Sama

作者: Adelaide Lawson


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-09-25 13:51:13 評論於
What is the current status of the manuscript? Requesting an update on the status.
(0) 讚! | Adelaide Lawson

作者: 蒙德锦玉


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-09-23 19:40:51 評論於
Have you received it? I have been pre-accepted for over a month and have been with the editor the whole time.
(0) 讚! | 蒙德锦玉

作者: 风陵齐心


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-08-30 16:08:11 評論於
May I ask how things are going?
(0) 讚! | 风陵齐心

作者: 只求能毕业--


領域: 医学
審稿時間: 9.0 month(s)
結果: 修改後接受


撰寫評論

2024-08-25 09:17:42 評論於
After half a year of waiting, I finally got accepted. After so many years of studying, I finally got a top publication half a year after graduation. I hope the journal will continue to improve! I hope my application for the Youth Fund next year will have a good result!
(0) 讚! | 只求能毕业--

作者: 尤金杰克


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-08-24 18:12:30 評論於
No translation needed.
(0) 讚! | 尤金杰克

作者: 一条小冬荷


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-08-17 21:40:32 評論於
Can I ask if you have got the results back?
(0) 讚! | 一条小冬荷

作者: 削月欣怿


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-08-16 14:16:53 評論於
Review speed: 6.0 | Submission acceptance rate: 50.0
Experience sharing: Can someone please explain why the publication is not allowing me to pay the page fees? I have sent several reminder emails, but they keep telling me to wait. Has anyone else experienced this before?
(0) 讚! | 削月欣怿

作者: 咏春顺慈


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-08-12 20:58:34 評論於
It has been reviewed for the third time, under review for a month, and then another two weeks for the dip. Is the editorial department on vacation? It shouldn't be this slow.
(0) 讚! | 咏春顺慈

作者: 尤金杰克


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-08-07 09:53:13 評論於
Review speed: 2.0 | Submission success rate: 25.0 Experience sharing: under review for a month.
(0) 讚! | 尤金杰克

作者: Adelaide Lawson


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-07-24 22:28:44 評論於
It generally takes several months to go from proof to online, ranging from a few days to a few weeks.
(0) 讚! | Adelaide Lawson

作者: 风陵齐心


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-07-18 10:12:36 評論於
How are you doing?
(0) 讚! | 风陵齐心

作者: 努力啊大凌春


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-07-10 23:00:38 評論於
May I ask how long it takes for the final proof to be ready? And how long until it is available online?
(0) 讚! | 努力啊大凌春

作者: 东风锦灏


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-07-02 17:33:30 評論於
+1

Translation: +1
(0) 讚! | 东风锦灏

首頁    上一頁    1    2    3    4    5    6    7    下一頁    末頁  (頁
/9)

開始撰寫 [Acta Pharmaceutica Sinica B] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*